0000000000240536

AUTHOR

S. Gallach Garcia

showing 6 related works from this author

Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy

2019

Abstract Background Lung cancer is the leading cause of cancer-related mortality worldwide. At diagnosis, 70% of patients present advanced disease being chemotherapy the standard of care. Although, specific tumour biomarkers that allow a better treatment selection and monitoring is absent at the moment. Enumeration and characterization of circulating tumor cells (CTCs) have the potential to perform as a prognostic biomarker for a precision medicine approach to lung cancer care. The present study was conducted to validate the characterization CTCs from patients with advanced Non-small cell lung cancer (NSCLC) as a valuable tool for anticipating the disease evolution and the therapy response.…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentHematologyPrecision medicinemedicine.diseaseCirculating tumor cellOncologyInternal medicinemedicineAdvanced diseasePrognostic biomarkerChristian ministryNon small cellLung cancerbusinessAnnals of Oncology
researchProduct

CD5 and CD6: Evaluation of their role as prognostic biomarkers in resectable non-small cell lung cancer

2018

Oncologymedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineHematologyNon small cellCD5businessLung cancermedicine.diseaseAnnals of Oncology
researchProduct

Analysis of immunoregulatory biomarkers in early stages of non-small cell lung cancer

2017

Oncologybusiness.industrymedicineCancer researchHematologyNon small cellLung cancermedicine.diseasebusinessAnnals of Oncology
researchProduct

Stemness characterization of tumorspheres from non-small cell lung cancer: Differential expression in CSC-related markers and signaling pathways

2017

Oncologybusiness.industrymedicineCancer researchHematologyNon small cellSignal transductionDifferential expressionLung cancermedicine.diseasebusinessAnnals of Oncology
researchProduct

Prognostic Impact of Vegfa in Resectable Non-Small-Cell Lung Cancer

2014

ABSTRACT Aim: Angiogenesis is a main process which happens in tumors and that promotes its growth, invasive capacity and metastasis. Host genetic variability within VEGF pathway may affect angiogenic signaling and alter patient's sensitivity to anti-angiogenic therapies and therefore the prognostic. The goal in the present study is to analyze the prognostic value of several SNPs in angiogenic genes and the relative expression of those genes, using a cohort of patients diagnosed with resectable non-small cell lung cancer. Methods: This study included 127 resectable (I-IIIA) NSCLC patients. RNA and DNA extractions from tissues were performed using Trizol®. 20 ng of DNA were used for studies o…

Oncologymedicine.medical_specialtyPathologybusiness.industrySingle-nucleotide polymorphismHematologymedicine.diseaseMetastasisVascular endothelial growth factor AOncologyInternal medicineGenotypemedicineTaqManAdenocarcinomabusinessLung cancerSurvival analysisAnnals of Oncology
researchProduct

1212P Exosomes cargo analysis as an approach to identify new biomarkers in NSCLC

2020

Oncologybusiness.industryCancer researchMedicineHematologybusinessMicrovesiclesAnnals of Oncology
researchProduct